TGTX insider trading
NasdaqCM HealthcareTG THERAPEUTICS, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About TG THERAPEUTICS, INC.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Company website: www.tgtherapeutics.com
TGTX insider activity at a glance
FilingIQ has scored 132 insider transactions for TGTX since Jul 8, 2015. The most recent filing in our index is dated Jun 11, 2026.
Across the full history, 3 open-market purchases
and 37 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on TGTX insider trades is 61.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest TGTX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding TGTX
Frequently asked
- How many insider trades does FilingIQ track for TGTX?
- FilingIQ tracks 132 Form 4 insider transactions for TGTX (TG THERAPEUTICS, INC.), covering filings from Jul 8, 2015 onwards. 5 of those were filed in the last 90 days.
- Are TGTX insiders net buyers or net sellers?
- Across the full Form 4 history for TGTX, 3 transactions (2%) were open-market purchases and 37 (28%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does TGTX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is TGTX in?
- TG THERAPEUTICS, INC. (TGTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $4.64B.
Methodology & sources
Every TGTX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.